Member Info for LlamaFarmer

Yes and no.

NO

Realistically - no, will need slightly longer to embed 001 and 002, then every chance, its only £100m or so 001 and 002 on their own are worth much more imo.

YES

But... patent cliff, pharma biz world is crazy

001, 002, 014, 015 for only £100m.

A silly bid could come at any time.

When it comes you will already need to hold stock!

Daffy, if you meant re the 15m offer to buy stock?

They've been running it this way for a while imo, the offer gets reloaded.

If you look at the time stamps on these trades the S.P. is being walked down!

Either a roll over or a bed n isa.

13-May-26 08:24:28 0.2211 5,000,000 Sell* 0.22 0.24 11.06k O

13-May-26 08:23:57 0.2251 5,000,000 Sell* 0.22 0.24 11.26k

That then triggers this sell at 0.22p...

13-May-26 08:25:09 0.22 5,000,000 Sell* 0.22 0.23 11.00k

Then this messed up transaction is corrected.

13-May-26 09:52:20 0.2138 5,200,000 Sell* 0.21 0.23 11.12k O

13-May-26 09:52:20 0.2138 -5,200,000 Unknown* 0.21 0.23 -11.12k O

13-May-26 09:52:20 0.2138 5,200,000 Sell* 0.21 0.23 11.12k

It's interesting that while this was going on you were being invited to sell up to 15m shares at 0.21p.

Someone's building a pot at a decent price aren't they?

Bones - 92 pence trade :) :)

Tug?

Fill the boat imo

This dip in price looks orchestrated to me.

Andy,

And he says ...

"At Solvonis Therapeutics, our US-focused SVN-002 programme in moderate-to-severe Alcohol Use Disorder is built around a related principle: using known pharmacology, disciplined clinical development and a defined regulatory strategy to pursue new treatment options for an underserved indication.

SVN-002 is being developed as a sublingual/buccal esketamine oral thin film with digital psychosocial support, with a planned 505(b)(2) pathway referencing Spravato®.

Repurposing is not a shortcut around evidence. It still requires appropriate bridging, robust clinical data and regulatory discipline.

But when done properly, it can be a powerful way to bring new treatment options to areas of major unmet need."

Water Tower Research could pick up Professor Nutts presentation, add Solvonis Therapeutics to the phase three Morecare trial / 001 slide and away we go.

Nutts presentation was so beautifully crafted from the eye leading to the brain diagram and onwards that the non specialists were led into how this science works, he could then expound upon his new Novel Molecules that weren't covered in depth..

This exchange comes from a June 1, 2010 BBC Radio 4 interview between Sue Lawley and Professor David Nutt, shortly after he was sacked from his role as Chairman of the Advisory Council on the Misuse of Drugs (ACMD)."I refused to resign.": Professor Nutt refused to step down voluntarily because he believed in the integrity of his evidence-based advice and felt that resigning would be an admission of wrongdoing, asserting that he was ultimately "sacked" by Home Secretary Alan Johnson."Crossed the line between scientific advice and policy.": This was the central argument from the government to justify his dismissal in October 2009. They argued that while the advisor gives evidence, the government must decide policy, and that Nutt was campaigning against government policy rather than providing impartial advice."Yes.": Professor Nutt acknowledged in the interview that he did indeed "cross the line" between purely scientific advising and openly challenging government policies when those policies were in direct conflict with scientific evidence (such as when he argued that alcohol was more harmful than ecstasy or cannabis).This event sparked a major debate in the UK about the independence of scientific advice in policy making

Https://www.reddit.com/r/IAmA/comments/2235ag/im_professor_david_nutt_sacked_for_telling_the/ |Truth about drugs and the founder of Drug Science

Got to admire this man for his dogged determination.

12 years later he was proved correct about the at the time younger voters and about our politicians pre and post power.

015 now in pre clinical trials funded by the U.S.A. Government with a new novel molecule from MDMA.

Ht tps:/ /t. me/+c WN-cU9agkBhYmM8

Newsflow about NHS data under one roof hitting mainstream.

Unsure if this is positive in anyway for f#ckback?

Would hope that Labour would pick low hanging fruit?

Htt ps :/ /t. me /+7_WgRydPSEQ1OTU0

Lose the spaces

*************+7_wgrydpseq1otu0

Jolli, do you use the last tea bag before you go out and buy some more?

Not 100% they will place, equally, so what if they do?

I'll leave you to it.

Bones, don't think my sense of humour is translating too well.

I've added this week, as I don't think any potential placing would be below this, which was me trying to be subtle with the head slap emoji.

I'll spell it out for the hard of understanding 😘

Look who took and are still holding the previous placings at 0.10,0.13,0.30 and 0.33p - well respected industry professionals, look how much money they've put into this, a lot more than any of us pi's - reputations on the line levels of investment? even if the company had to place and the price was here, I'm still confident everything works out.

Do need to be realistic, companies do raise, this business has been good at raising and spending frugally, if another one comes - so what, history shows they will attempt to drive the business forwards.

My scenario is, read the rns info and add it together.

Usa - water Tower to initiate coverage, Professor Nutt teed it up beautifully the other night, mentioned the phase 3, ketamin aud trial of Dr Celia Morgan at Exeter - one Google away from 001 and Solvonis, spoke about Ketemain, AUD and new novel molecules - transpose all that into WTR fireside chat or podcast and off we go.

Already received non dilutive grant funding from Nida for 015 coke and meth - seeking UK, EU and USA funding on rest of pipeline, head of Nida was running Nutts presentation.

Ai still throwing out findings.

001 banner headline being retained, then gets promoted hard, id like them to retain it until 2028/29 but might be forced to sell once usa sees what they have?

002 -bridging data being worked on - needs toxicology, once that enters phase iib could easily attract bids - again look for non dilutive funding.

With usa coverage is there a nasdaq listed vehicle where synergies can join?

Today someone thinks it's going to be under 0.2334 🤦

Sarcasm m8.

Someone obviously thinks it will be less than 0.24p?

We know they will place before year end as the cash runway is until 12/26.

That they are now actively promoting Solvonis and 001 in the USA is of interest.

The meeting yesterday had the U.S. decision makers that cover 001, 002 ( Dr Koob NIAAA ) and 015 (Dr Volker NIDA).

Going to get interesting once the American audience is shown the progress on 001 and 002, especially the ongoing bridging work to Spravato which will be very well known to their investing communities.

N.b.

Mason and Koob ran Scripps Research.

Dr George Koob developed the neurocircuitry theory of addiction, now runs the

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

His wife Dr Barbara Mason used to be part of Awakn and sat on the panel along with Dr Celia Morgan.

https://www.biospace.com/awakn-life-sciences-announces-the-addition-of-renowned-substance-addiction-researcher-professor-barbara-mason-to-its-clinical-advisory-board.

Previously they jointly ran Scripps research a 100 year old institution for life sciences.

https://www.scripps.edu/

The chair today Dr Nora Volker runs NIDA the National Institute On Drug Abuse who are funding 015 - meth and coke.

Today's talk ( as far as we are concerned ) was the soft launch for Ketamin based products( Dr Celia Morgans 001, LTS Lohanns 002 and his new novel molecules (015 meth & coke)).

Game On!